Abstract
Background
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography ((PET) safely predicts axillary status in patients with breast cancer, but is not sufficiently accurate in early breast cancer patients. This study analyzed the value of 18F-FDG PET/computed tomography (CT) with contrast enhancement in detecting axillary lymph node involvement in T1 breast cancer patients.
Methods
Contrast-enhanced 18F-FDG PET/CT was performed within 20 days of surgery in 143 breast cancer patients with tumors ≤2 cm in size. The patients underwent either axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB), and histopathology reports were used to provide the definitive diagnosis against which the contrast-enhanced 18F-FDG PET/CT study results were compared.
Results
The sensitivity, specificity, and negative and positive predictive values of contrast-enhanced 18F-FDG PET/CT in detecting axillary involvement were 70.0%, 92.2%, 88.8%, and 77.8%, respectively, in the entire series of 143 patients, with eight false-positive and 12 false negative results. The false-negative results were associated with the number of metastatic lymph nodes and the rate of FDG uptake.
Conclusion
Contrast-enhanced 18F-FDG PET/CT cannot replace histologic staging using SLNB in patients with breast cancer, but 18F-FDG PET/CT increases the sensitivity for predicting axillary node metastasis, and allows for a selective approach to either ALND or SLNB, even in patients with T1 breast cancer.
Similar content being viewed by others
References
Miller WR, Ellis IO, Sainsbury JR, Dixon JM (1994) ABC of breast diseases. Prognostic factors BMJ 309:1573–1576
Amersi F, Hansen NM (2006) The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol 7:141–151
Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187
Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA (2002) Chronic arm morbidity after curative breast cancer treatment:prevalence and impact on quality of life. J Clin Oncol 20:4242–4248
Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A (2006) Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 93:109–119
McCready D, Holloway C, Shelley W, Down N, Robinson P, Sinclair S et al (2005) Surgical management of early stage invasive breast cancer: a practice guideline. Can J Surg 48(3):185–194
de Freitas R, Jr CMV, Schneider SV, Nicolau MA, Marussi E (1991) Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 17(3):240–244
Sismondi P, Ponzone R, Biglia N, Roagna R, Cacciari F, Maggiorotto F (2003) Sentinel node biopsy for breast cancer: yes, less surgery is better surgery. Eur J Gynaecol Oncol 24(2):107–112
Gipponi M, Bassetti C, Canavese G, Catturich A, Di Somma C, Vecchio C et al (2004) Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J Surg Oncol 85(3):102–111
Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography in selected cancers. Health Technol Assess 11(44):iii–iv, xi-267
Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M et al (1998) Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 228:220–227
Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473–478
Wahl RL, Siegel BA, Coleman RE, Gatsonis CG; PET Study Group (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22:277–285
Weir L, Worsley D, Bernstein V (2005) The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 11:204–209
Blodgett TM, Meltzer CC, Townsend DW (2007) PET/CT: form and function. Radiology 242:360–385
Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL (1993) Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 3:743–750
Bombardieri E, Crippa F, Maffioli L, Chiti A, Castellani MR, Greco M et al (1996) Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: can positron emission tomography (PET) with 18F-FDG be considered as the best method? Int J Oncol 8:693–699
Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, et al (2001) 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19(15):3516–3523
Danforth DN, Aloj L, Carrasquillo JA, Bacharach SL, Chow C, Zujewski J et al (2002) The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 75:135–146
Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93:707–712
van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D et al (2002) Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619–624
Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33(3):254–262
Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N et al (2008) Utility of 18F-fluorodeoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer8:165
Kim J, Lee J, Chang E, Kim S, Suh K, Sul J et al (2009) Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 33:943–949
Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H et al (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71(2):171–173
Yang JH, Nam SJ, Lee TS, Lee HK, Jung SH, Kim BT (2001) Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31:1–6
Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U et al (2004) Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10:89–93
Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502
Samson D, Flamm CR, Aronson N (2001) FDG positron emission tomography for evaluating breast cancer. Blue Cross and Blue Shield Association, Chicago
Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G et al (1991) Noninvasive grading of musculoskeletal tumor using PET. J Nucl Med 32:1508–1512
Reisser C, Haberkorn V, Strauss LG (1993) The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J Otolaryngol 22:231–238
Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B (1995) Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med 35:1790–1796
Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H (1996) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34:1–6
Zhuang HM, Cortes-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martinez-Lazaro R et al (2001) Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 22:1123–1128
Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E (2004) FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 31(Suppl 1):S97–S102
Greco M, Agresti R, Cascinelli N, Casalini P, Giovanazzi R, Maucione A et al (2000) Breast cancer patients treated without axillary surgery: clinical implication and biologic analysis. Ann Surg 232:1–7
Acknowledgements
This research was supported by the Yeungnam University research grants in 2008.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kong, E.J., Chun, K.A., Cho, I.H. et al. 18F-FDG PET/CT with Contrast Enhancement for Evaluation of Axillary Lymph Node Involvement in T1 Breast Cancer. Nucl Med Mol Imaging 44, 170–176 (2010). https://doi.org/10.1007/s13139-010-0035-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-010-0035-y